Redox‐ and Hypoxia‐Responsive MRI Contrast Agents

The development of responsive or “smart” magnetic resonance imaging (MRI) contrast agents that can report specific biomarker or biological events has been the focus of MRI contrast agent research over the past 20 years. Among various biological hallmarks of interest, tissue redox and hypoxia are particularly important owing to their roles in disease states and metabolic consequences. Herein we review the development of redox‐/hypoxia‐sensitive T1 shortening and paramagnetic chemical exchange saturation transfer (PARACEST) MRI contrast agents. Traditionally, the relaxivity of redox‐sensitive Gd3+‐based complexes is modulated through changes in the ligand structure or molecular rotation, while PARACEST sensors exploit the sensitivity of the metal‐bound water exchange rate to electronic effects of the ligand‐pendant arms and alterations in the coordination geometry. Newer designs involve complexes of redox‐active metal ions in which the oxidation states have different magnetic properties. The challenges of translating redox‐ and hypoxia‐sensitive agents in vivo are also addressed.

[1]  A. Sherry,et al.  Europium(III) DOTA-tetraamide complexes as redox-active MRI sensors. , 2012, Journal of the American Chemical Society.

[2]  H. Machulla Imaging of Hypoxia , 1999, Developments in Nuclear Medicine.

[3]  D. Fagret,et al.  Nitroimidazoles and hypoxia imaging: synthesis of three technetium-99m complexes bearing a nitroimidazole group: biological results. , 2001, Bioorganic & medicinal chemistry letters.

[4]  É. Tóth,et al.  Similarities and differences between the isoelectronic GdIII and EuII complexes with regard to MRI contrast agent applications , 2001 .

[5]  Éva Tóth,et al.  The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging , 2013 .

[6]  R. Scopelliti,et al.  Solution and solid-state characterization of Eu(II) chelates: a possible route towards redox responsive MRI contrast agents. , 2000, Chemistry.

[7]  S. K. Imam Review of positron emission tomography tracers for imaging of tumor hypoxia. , 2010, Cancer biotherapy & radiopharmaceuticals.

[8]  A. Nunn,et al.  Nitroimidazoles and imaging hypoxia , 1995, European Journal of Nuclear Medicine.

[9]  D. Befroy,et al.  Magnetic Resonance Spectroscopy Studies of Human Metabolism , 2011, Diabetes.

[10]  Shreya Mukherjee,et al.  Redox-activated manganese-based MR contrast agent. , 2013, Journal of the American Chemical Society.

[11]  J. Ballinger,et al.  Imaging hypoxia in tumors. , 2001, Seminars in nuclear medicine.

[12]  A. Sherry,et al.  A responsive europium(III) chelate that provides a direct readout of pH by MRI. , 2010, Journal of the American Chemical Society.

[13]  Enzo Terreno,et al.  Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. , 2009, Accounts of chemical research.

[14]  Ciprian Catana,et al.  Bimodal MR-PET agent for quantitative pH imaging. , 2010, Angewandte Chemie.

[15]  D. Lee,et al.  Synthesis of 68Ga-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers. , 2011, Bioorganic & medicinal chemistry.

[16]  James B. Mitchell,et al.  Electron Paramagnetic Resonance Imaging of Tumor pO2 , 2012, Radiation research.

[17]  S. Aime,et al.  Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.

[18]  Xilin Sun,et al.  Tumor Hypoxia Imaging , 2011, Molecular Imaging and Biology.

[19]  C. Vandeputte,et al.  A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol , 1994, Cell Biology and Toxicology.

[20]  M. Allen,et al.  Developments in the Coordination Chemistry of Europium(II). , 2012, European journal of inorganic chemistry.

[21]  Zejun Li,et al.  Recent advances on radionuclide labeled hypoxia-imaging agents. , 2012, Current pharmaceutical design.

[22]  Robert J Gillies,et al.  Renal and systemic pH imaging by contrast‐enhanced MRI , 2003, Magnetic resonance in medicine.

[23]  A. Sherry,et al.  Modulation of CEST images in vivo by T1 relaxation: a new approach in the design of responsive PARACEST agents. , 2013, Journal of the American Chemical Society.

[24]  Garry Berkovic,et al.  Spiropyrans and Spirooxazines for Memories and Switches. , 2000, Chemical reviews.

[25]  A. Nunn,et al.  Can receptors be imaged with MRI agents? , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[26]  Peter Caravan,et al.  Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. , 2009, Accounts of chemical research.

[27]  A. Sherry,et al.  A europium(III)-based PARACEST agent for sensing singlet oxygen by MRI. , 2013, Dalton transactions.

[28]  E. Terreno,et al.  A R2/R1 ratiometric procedure for a concentration-independent, pH-responsive, Gd(III)-based MRI agent. , 2006, Journal of the American Chemical Society.

[29]  J. D. Chapman,et al.  The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. Morrow,et al.  Macrocyclic Ligands for Fe(II) ParaCEST and Chemical Shift MRI Contrast Agents , 2012 .

[31]  Angelique Louie,et al.  MRI biosensors: A short primer , 2013, Journal of magnetic resonance imaging : JMRI.

[32]  J. Zweier,et al.  Development of functional electron paramagnetic resonance imaging. , 1998, Breast disease.

[33]  A. Sherry,et al.  The importance of water exchange rates in the design of responsive agents for MRI. , 2013, Current opinion in chemical biology.

[34]  A. Sherry,et al.  Modulation of water exchange in europium(III) DOTA-tetraamide complexes via electronic substituent effects. , 2008, Journal of the American Chemical Society.

[35]  E. Gianolio,et al.  Exofacial protein thiols as a route for the internalization of Gd(III)-based complexes for magnetic resonance imaging cell labeling. , 2010, Journal of medicinal chemistry.

[36]  K. Jain Textbook of Hyperbaric Medicine , 1995 .

[37]  A. Sherry,et al.  Synthesis and characterization of a hypoxia-sensitive MRI probe. , 2012, Chemistry.

[38]  S. Aime,et al.  Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds. , 2007, Dalton transactions.

[39]  Christophe Van de Wiele,et al.  Molecular imaging of hypoxia with radiolabelled agents , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  A. Torres,et al.  Exploiting cell surface thiols to enhance cellular uptake. , 2012, Trends in biotechnology.

[41]  Murali C Krishna,et al.  In vivo measurement of regional oxygenation and imaging of redox status in RIF‐1 murine tumor: Effect of carbogen‐breathing , 2002, Magnetic resonance in medicine.

[42]  John Kurhanewicz,et al.  Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging , 2011, Proceedings of the National Academy of Sciences.

[43]  GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo , 2014, JBIC Journal of Biological Inorganic Chemistry.

[44]  J. Morrow,et al.  A redox-activated MRI contrast agent that switches between paramagnetic and diamagnetic states. , 2013, Angewandte Chemie.

[45]  L. Hall,et al.  Roles for paramagnetic substances in MRI: contrast agents, molecular amplifiers, and indicators for redox and pH mapping , 1994, Magnetic Resonance Materials in Physics, Biology and Medicine.

[46]  Wei Chen,et al.  Intracellular redox state revealed by in vivo 31P MRS measurement of NAD+ and NADH contents in brains , 2014, Magnetic resonance in medicine.

[47]  H. Nagasawa,et al.  2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia. , 2012, Bioconjugate chemistry.

[48]  S. Amir,et al.  Hypoxia-inducible factor (HIF) in human tumorigenesis. , 2007, Histology and histopathology.

[49]  J. Jeong,et al.  Hypoxia imaging agents labeled with positron emitters. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[50]  G. Semenza,et al.  Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. , 2001, Trends in molecular medicine.

[51]  K. Hanaoka,et al.  Development of hypoxia-sensitive Gd3+-based MRI contrast agents. , 2012, Bioorganic & medicinal chemistry letters.

[52]  Zoltan Kovacs,et al.  Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. , 2010, Chemical reviews.

[53]  Comparison of divalent transition metal ion paraCEST MRI contrast agents , 2014, JBIC Journal of Biological Inorganic Chemistry.

[54]  P. Ghezzi,et al.  Regulation of redox-sensitive exofacial protein thiols in CHO cells , 2006, Biological chemistry.

[55]  V. Lushchak,et al.  Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions , 2012, Journal of amino acids.

[56]  E. Haacke,et al.  Eu(II)-containing cryptates as contrast agents for ultra-high field strength magnetic resonance imaging. , 2011, Chemical communications.

[57]  James B. Mitchell,et al.  Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. , 2002, Cancer research.

[58]  N. Raghunand,et al.  Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. , 2012, Translational oncology.

[59]  G. Semenza,et al.  Regulation of cancer cell metabolism by hypoxia-inducible factor 1. , 2009, Seminars in cancer biology.

[60]  R. Gillies,et al.  Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents , 2011, NMR in biomedicine.

[61]  T. Hagen Oxidative stress, redox imbalance, and the aging process. , 2003, Antioxidants & redox signaling.

[62]  Janet R Morrow,et al.  Redox-activated MRI contrast agents based on lanthanide and transition metal ions. , 2014, Journal of inorganic biochemistry.

[63]  The Development of Iron(II) Complexes as ParaCEST MRI Contrast Agents , 2012 .

[64]  B. Brüne,et al.  Tumor hypoxia and cancer progression. , 2006, Cancer letters.

[65]  F. Gallagher,et al.  Hyperpolarized [1-13C]-Ascorbic and Dehydroascorbic Acid: Vitamin C as a Probe for Imaging Redox Status in Vivo , 2011, Journal of the American Chemical Society.

[66]  C. Koch,et al.  Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. , 2003, Advances in experimental medicine and biology.

[67]  R. Gillies,et al.  Redox‐sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin , 2006, Magnetic resonance in medicine.

[68]  Enzo Terreno,et al.  Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. , 2005, Angewandte Chemie.

[69]  Enzo Terreno,et al.  Gadolinium-doped LipoCEST agents: a potential novel class of dual 1H-MRI probes. , 2011, Chemical communications.

[70]  Kenneth A Krohn,et al.  Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.

[71]  Thomas J Meade,et al.  Bioresponsive, cell-penetrating, and multimeric MR contrast agents. , 2009, Accounts of chemical research.

[72]  Mark D Pagel,et al.  An overview of responsive MRI contrast agents for molecular imaging. , 2008, Frontiers in bioscience : a journal and virtual library.

[73]  T. Clanton Hypoxia-induced reactive oxygen species formation in skeletal muscle. , 2007, Journal of applied physiology.

[74]  E. Terreno,et al.  Metal containing nanosized systems for MR-Molecular Imaging applications , 2008 .

[75]  A Dean Sherry,et al.  Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. , 2006, Chemical Society reviews.

[76]  A. Sherry,et al.  Stability and Toxicity of Contrast Agents , 2013 .

[77]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[78]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[79]  A. Louie,et al.  Multimodal magnetic-resonance/optical-imaging contrast agent sensitive to NADH. , 2009, Angewandte Chemie.

[80]  A. Louie,et al.  Photochromically-controlled, reversibly-activated MRI and optical contrast agent. , 2007, Chemical communications.

[81]  M. Allen,et al.  Interaction of Biphenyl-Functionalized Eu(2+)-Containing Cryptate with Albumin: Implications to Contrast Agents in Magnetic Resonance Imaging. , 2012, Inorganica chimica acta.

[82]  B. Tang,et al.  High selectivity imaging of nitroreductase using a near-infrared fluorescence probe in hypoxic tumor. , 2013, Chemical communications.

[83]  J. Martinelli,et al.  Cleavable β-cyclodextrin nanocapsules incorporating Gd(III)-chelates as bioresponsive MRI probes. , 2011, Chemical communications.

[84]  N. Raghunand,et al.  Redox-active magnetic resonance imaging contrast agents: studies with thiol-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid derivatives. , 2012, Journal of medicinal chemistry.

[85]  Enzo Terreno,et al.  Challenges for molecular magnetic resonance imaging. , 2010, Chemical reviews.

[86]  M. Bache,et al.  Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. , 2008, Current medicinal chemistry.

[87]  Irfan Rahman,et al.  Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method , 2006, Nature Protocols.

[88]  S. Mueller,et al.  (1)H MRS detection of glycine residue of reduced glutathione in vivo. , 2010, Journal of magnetic resonance.

[89]  R. Beyers,et al.  A magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide. , 2012, Inorganic chemistry.

[90]  D. Koh,et al.  Imaging hypoxia in tumours with advanced MRI. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[91]  Aimé,et al.  A p(O(2))-Responsive MRI Contrast Agent Based on the Redox Switch of Manganese(II / III) - Porphyrin Complexes. , 2000, Angewandte Chemie.

[92]  Juyoung Yoon,et al.  Fluorescent and luminescent probes for detection of reactive oxygen and nitrogen species. , 2011, Chemical Society reviews.

[93]  W. Schafer,et al.  Oxygen Homeostasis: How the Worm Adapts to Variable Oxygen Levels , 2008, Current Biology.

[94]  P. Brookes,et al.  Measurement of extracellular (exofacial) versus intracellular protein thiols. , 2010, Methods in enzymology.

[95]  M. Dewhirst,et al.  Molecular Imaging of Hypoxia , 2011, The Journal of Nuclear Medicine.

[96]  S Aime,et al.  pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. , 2001, Journal of the American Chemical Society.

[97]  G. Scorza,et al.  Hypoxia-stimulated reduction of doxyl stearic acids in human red blood cells. Role of hemoglobin. , 1991, Biochimica et biophysica acta.

[98]  E. Gianolio,et al.  In vivo labeling of B16 melanoma tumor xenograft with a thiol-reactive gadolinium based MRI contrast agent. , 2011, Molecular pharmaceutics.

[99]  D. Harrison,et al.  Methods for detection of mitochondrial and cellular reactive oxygen species. , 2014, Antioxidants & redox signaling.

[100]  J. Morrow,et al.  The NiCEST approach: nickel(II) paraCEST MRI contrast agents. , 2012, Journal of the American Chemical Society.

[101]  Rosario Scopelliti,et al.  EuII-cryptate with optimal water exchange and electronic relaxation: a synthon for potential pO2 responsive macromolecular MRI contrast agents. , 2002, Chemical communications.

[102]  E. Gianolio,et al.  Dual MRI-SPECT agent for pH-mapping. , 2011, Chemical communications.

[103]  N. Ballatori,et al.  Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. , 2009, Molecular aspects of medicine.

[104]  E. Gianolio,et al.  Targeting exofacial protein thiols with Gd(III) complexes. An efficient procedure for MRI cell labelling. , 2009, Chemical communications.

[105]  N. Soh Recent advances in fluorescent probes for the detection of reactive oxygen species , 2006, Analytical and bioanalytical chemistry.

[106]  M. Allen,et al.  Oxidatively stable, aqueous europium(II) complexes through steric and electronic manipulation of cryptand coordination chemistry. , 2010, Angewandte Chemie.

[107]  T. Oberley,et al.  Extracellular/microenvironmental redox state. , 2010, Antioxidants & redox signaling.

[108]  J. Morrow,et al.  CoCEST: cobalt(II) amide-appended paraCEST MRI contrast agents. , 2013, Chemical communications.

[109]  M. Allen,et al.  Physical Properties of Eu(2+)-Containing Cryptates as Contrast Agents for Ultra-High Field Magnetic Resonance Imaging. , 2012, European journal of inorganic chemistry.

[110]  A. Louie,et al.  Synthesis and characterization of a redox- and light-sensitive MRI contrast agent. , 2009, Tetrahedron.

[111]  H. Jun,et al.  Recent advances in insulin gene therapy for type 1 diabetes. , 2002, Trends in molecular medicine.

[112]  J. Morrow,et al.  Iron(II) PARACEST MRI contrast agents. , 2011, Journal of the American Chemical Society.

[113]  James B. Mitchell,et al.  Intracellular hypoxia of tumor tissue estimated by noninvasive electron paramagnetic resonance oximetry technique using paramagnetic probes. , 2011, Biological & pharmaceutical bulletin.

[114]  N. Raghunand,et al.  Design, synthesis, and evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid derived, redox-sensitive contrast agents for magnetic resonance imaging. , 2010, Journal of medicinal chemistry.

[115]  Peng Huang,et al.  Redox regulation of cell survival. , 2008, Antioxidants & redox signaling.

[116]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[117]  Christopher J. Chang,et al.  A hydrogen peroxide-responsive hyperpolarized 13C MRI contrast agent. , 2011, Journal of the American Chemical Society.

[118]  I. Tannock,et al.  Acid pH in tumors and its potential for therapeutic exploitation. , 1989, Cancer research.

[119]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[120]  James B. Mitchell,et al.  In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. , 1998, Cancer research.

[121]  Matthew E Merritt,et al.  Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI , 2005, Magnetic resonance in medicine.

[122]  H. Kurihara,et al.  Radiolabelled agents for PET imaging of tumor hypoxia. , 2012, Current medicinal chemistry.

[123]  Henry Jay Forman,et al.  Redox signaling , 2004, Molecular and Cellular Biochemistry.

[124]  M. Alber,et al.  Imaging oxygenation of human tumours , 2006, European Radiology.

[125]  Robert E Lenkinski,et al.  PARACEST agents: modulating MRI contrast via water proton exchange. , 2003, Accounts of chemical research.

[126]  Dawen Zhao,et al.  Measuring changes in tumor oxygenation. , 2004, Methods in enzymology.

[127]  James L Tatum,et al.  Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy , 2006, International journal of radiation biology.

[128]  Robert J Gillies,et al.  High resolution pHe imaging of rat glioma using pH‐dependent relaxivity , 2006, Magnetic resonance in medicine.